Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708095 · ClinicalTrials.gov registry record · Phase 2
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
- 20
- Study locations
NCT02708095 is a Phase 2 study of Systemic Lupus Erythematosus that has completed, run by Eli Lilly and Company. The registered enrollment target is 314 participants, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02708095, a Phase 2 study of Systemic Lupus Erythematosus, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baricitinib
Study Locations (20)
California
- Wallace Rheumatic Study Center - Beverly Hills
- Medvin Clinical Research - Covina
- TriWest Research Assocaites - El Cajon
- University of California - La Jolla
- Desert Medical Advances - Palm Desert
- Inlande Rheumatology Clinical Trials - Upland
Florida
- New Horizon Research Center - Miami
- West Broward Rheumatology Associates, Inc - Tamarac
- Clinical Research of West Florida, Inc. - Tampa
Louisiana
- The Arthritis & Diabetes Clinic Inc. - Monroe
- Louisiana State University Health Sciences Center - Shreveport
Missouri
- Clayton Medical Research - St Louis
- Arthritis Consultants - St Louis
Arizona
- University of Arizona - Tucson
Colorado
- Denver Arthritis Center - Denver
Kansas
- Kansas City Internal Medicine Research - Overland Park
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2016-03-24 |
| Est. Completion | 2017-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02708095
The ClinicalTrials.gov registry entry for NCT02708095 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (17% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02708095 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT02708095 about?
NCT02708095 is a clinical study titled "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)". The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
What is the current status of trial NCT02708095?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2016-03-24. Estimated completion is 2017-11-09.
What conditions does trial NCT02708095 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT02708095?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT02708095?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02708095 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.